This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in
treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with
daratumumab may induce changes in body's immune system and may interfere with the ability of
cancer cells to grow and spread. Drugs used in chemotherapy, such as pomalidomide and
dexamethasone, work in different ways to stop the growth of cancer cells, either by killing
the cells, by stopping them from dividing, or by stopping them from spreading. Giving
daratumumab with dexamethasone and pomalidomide may work bettering in treating patient
compared to dexamethasone and pomalidomide alone.
I. To determine the overall response rate (partial response [PR], very good partial response
[VGPR], complete response [CR], or stringent complete response [sCR]) of daratumumab
retreatment in combination with pomalidomide and dexamethasone (DPd) in patients with
relapsed refractory multiple myeloma.
I. To assess progression free survival and overall survival associated with retreatment with
daratumumab in combination with pomalidomide and dexamethasone (DPd) in patients with
relapsed and refractory multiple myeloma.
II. To determine the toxicities associated with retreatment with daratumumab in combination
with pomalidomide and dexamethasone (DPd).
Patients receive pomalidomide orally (PO) once daily (QD) on days 1-21 and daratumumab
intravenously (IV) on days 1, 8, 15, and 22 of cycles 1-2, days 1-15 of cycles 3-6, and day 1
of subsequent cycles. Patients also receive dexamethasone PO on days 1, 8, 15, and 22 of
cycles 1-12. Cycles every 28 days in the absence of disease progression or unacceptable
After completion of study treatment, patients are followed up for every 3 months until
subsequent treatment or progressive disease, then every 6 months for up to 3 years.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.